BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32947313)

  • 1. The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer.
    Dohopolski M; Hannan R; Wardak Z; Hammers H; Garant A
    Cancer J; 2020; 26(5):448-459. PubMed ID: 32947313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
    Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
    Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
    Raj RK; Upadhyay R; Wang SJ; Singer EA; Dason S
    Curr Oncol; 2023 Dec; 30(12):10283-10298. PubMed ID: 38132383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma.
    Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S
    Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
    Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.
    Siva S; Kothari G; Muacevic A; Louie AV; Slotman BJ; Teh BS; Lo SS
    Nat Rev Urol; 2017 Sep; 14(9):549-563. PubMed ID: 28631740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic Body Radiotherapy for Kidney Cancer: Ready for Prime Time?
    Carrasco-Esteban E; Barrionuevo-Castillo P; Domínguez-Rullán J; Gómez-Aparicio MA; Ferri-Molina M; Sáez-Bueno P; Zalabarría-Zarrabeitia Z; Scorsetti M; Arcangeli S; López-Campos F; Couñago F
    Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):163-176. PubMed ID: 36443137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation Therapy for Patients with Advanced Renal Cell Carcinoma.
    Miccio JA; Oladeru OT; Jun Ma S; Johung KL
    Urol Clin North Am; 2020 Aug; 47(3):399-411. PubMed ID: 32600541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
    Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
    Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
    Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.
    Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D
    Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma.
    Zalay O; Mehra P; Pereira I; Malone J; Malone S
    World J Urol; 2024 Jan; 42(1):52. PubMed ID: 38244135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma.
    Dason S; Lacuna K; Hannan R; Singer EA; Runcie K
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390038. PubMed ID: 37253211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.
    Ranck MC; Golden DW; Corbin KS; Hasselle MD; Liauw SL; Stadler WM; Hahn OM; Weichselbaum RR; Salama JK
    Am J Clin Oncol; 2013 Dec; 36(6):589-95. PubMed ID: 22868242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
    Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
    Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
    BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
    Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
    Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy.
    Miccio J; Johung K
    Oncology (Williston Park); 2019 May; 33(5):167-73, 177. PubMed ID: 31095714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review.
    Kothari G; Foroudi F; Gill S; Corcoran NM; Siva S
    Acta Oncol; 2015 Feb; 54(2):148-57. PubMed ID: 25140860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
    Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
    Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.